Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta- blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Additive effects leading to bradycardia (which may result in syncope) have been reported with the
combined use of various beta-blockers (including atenolol) and rivastigmine. Cardiovascular beta-
blockers are expected to be associated with the greatest risk, but reports have also been received in
patients using other beta-blockers. Therefore, caution should be exercised when rivastigmine is
combined with beta-blockers and also other bradycardia agents (e.g.class III antiarrhythmic agents,
calcium channel antagonists, digitalis glycoside, pilocarpin).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-04-15T14:03:00Z · SHA-256 84780fda687229b6eb4fb8cc5e55f033116dac099756163d6052747dd50b9054 · Passage 3588ba7dc13509610e7b818e2cd1233ae4b625de85b8fc90e5c633d981b10ec2 · Zeichen 641–1197 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.